Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome.

Biotechnology

Emalex Biosciences

Eric Messner

Tim Rudolphi

Jose Zapata

Trish Rice

Sarah Atkinson

Paul Reinfelds

Doug Frandsen

Christine H. Soulje

Frederick Munschauer

Tom Stothoff

Jenny Swalec

Jay White

Leadership Team

Regulatory Affairs and Quality Assurance

Clinical Operations

Teams at Emalex Biosciences

Leadership Team

Regulatory Affairs and Quality Assurance

Clinical Operations